Gemcitabine

Results: 207



#Item
11 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Gemzar safely and effectively. See full prescribing information for Gemzar. GEMZAR (gemcitabine for injection), fo

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Gemzar safely and effectively. See full prescribing information for Gemzar. GEMZAR (gemcitabine for injection), fo

Add to Reading List

Source URL: pi.lilly.com

Language: English - Date: 2018-05-23 09:14:22
    2Final Results of a Phase 1b of Tarextumab (OMP-59R5) (anti-Notch2/3 antibody) in Combination with Nab-paclitaxel and Gemcitabine (Nab P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC): ALPINE Stu

    Final Results of a Phase 1b of Tarextumab (OMP-59R5) (anti-Notch2/3 antibody) in Combination with Nab-paclitaxel and Gemcitabine (Nab P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC): ALPINE Stu

    Add to Reading List

    Source URL: s3.amazonaws.com

    - Date: 2014-09-25 16:16:37
      3Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Colin Weekes,1

      Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Colin Weekes,1

      Add to Reading List

      Source URL: publications.oncomed.com

      - Date: 2016-10-09 05:13:10
        4Preclinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer Manuel Hidalgo*, Antonio Cubillo*, Robert Stagg**, Jakob Dupont**, Wan-Ching Yen**, Tim

        Preclinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer Manuel Hidalgo*, Antonio Cubillo*, Robert Stagg**, Jakob Dupont**, Wan-Ching Yen**, Tim

        Add to Reading List

        Source URL: s3.amazonaws.com

        - Date: 2014-11-19 14:29:44
          5A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

          A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

          Add to Reading List

          Source URL: posters.omed.s3.amazonaws.com

          - Date: 2016-01-22 10:42:40
            6Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Wells Messersmith,1

            Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Wells Messersmith,1

            Add to Reading List

            Source URL: publications.oncomed.com

            - Date: 2016-10-08 04:07:44
              7A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM

              A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM

              Add to Reading List

              Source URL: s3.amazonaws.com

              - Date: 2014-09-25 16:14:56
                8Final Results of a Phase 1b of Tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in Combination with Nab-paclitaxel and Gemcitabine (Nab P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC): ALPINE Study E

                Final Results of a Phase 1b of Tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in Combination with Nab-paclitaxel and Gemcitabine (Nab P+Gem) in Patients (pts) with Untreated Metastatic Pancreatic Cancer (mPC): ALPINE Study E

                Add to Reading List

                Source URL: s3.amazonaws.com

                - Date: 2015-01-16 14:31:43
                  9TACTIC: Phase 2 trial of panitumumab, cisplatin and gemcitabine in biliary tract cancer The TACTIC trial is helping researchers answer an important health question. It is providing evidence on whether panitumumab (Vectib

                  TACTIC: Phase 2 trial of panitumumab, cisplatin and gemcitabine in biliary tract cancer The TACTIC trial is helping researchers answer an important health question. It is providing evidence on whether panitumumab (Vectib

                  Add to Reading List

                  Source URL: www.ctc.usyd.edu.au

                  - Date: 2016-07-01 01:28:40
                    10#3129 Predictive biomarker identification for response of vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts Chun Zhang, Fiore Cattaruzza, Pete Yeung, Wan-Ching Yen, Ma

                    #3129 Predictive biomarker identification for response of vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts Chun Zhang, Fiore Cattaruzza, Pete Yeung, Wan-Ching Yen, Ma

                    Add to Reading List

                    Source URL: posters.omed.s3.amazonaws.com

                    Language: English - Date: 2016-04-18 15:47:23